OUTLOOK THERAPEUTICS, INC. Finance Lease, Liability
OUTLOOK THERAPEUTICS, INC. (OTLK) had Finance Lease, Liability of $1.08 thousand as of 2023-12-31, per its 10-Q filed 2024-02-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:FinanceLeaseLiability · last filed 2024-12-27
- 2023-12-31: Finance Lease, Liability $1.08K.
- 2023-09-30: Finance Lease, Liability $4.27K.
- 2023-06-30: Finance Lease, Liability $7.35K.
- 2023-03-31: Finance Lease, Liability $10.33K.
| Period end | Finance Lease, Liability |
|---|---|
| 2023-12-31 | $1.08K 10-Q · filed 2024-02-14 |
| 2023-09-30 | $4.27K 10-K · filed 2024-12-27 |
| 2023-06-30 | $7.35K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $10.33K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $13.22K 10-Q · filed 2023-02-14 |
| 2022-09-30 | $16.02K 10-K · filed 2023-12-22 |
| 2022-06-30 | $21.70K 10-Q · filed 2022-08-10 |
| 2022-03-31 | $28.75K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $35.68K 10-Q · filed 2022-02-14 |
| 2021-09-30 | $42.48K 10-K · filed 2022-12-29 |
| 2021-06-30 | $49.16K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $55.73K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $62.18K 10-Q · filed 2021-02-16 |
| 2020-09-30 | $72.26K 10-K · filed 2021-12-23 |
| 2020-06-30 | $101.87K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $12.69M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $13.18M 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |